Discovery of first-in-class nanomolar inhibitors of heptosyltransferase I reveals a new aminoglycoside target and potential alternative mechanism of action

A clinically relevant inhibitor for Heptosyltransferase I (HepI) has been sought after for many years because of its critical role in the biosynthesis of lipopolysaccharides on bacterial cell surfaces. While many labs have discovered or designed novel small molecule inhibitors, these compounds lacke...

Descripción completa

Detalles Bibliográficos
Autores principales: Milicaj, Jozafina, Hassan, Bakar A., Cote, Joy M., Ramirez-Mondragon, Carlos A., Jaunbocus, Nadiya, Rafalowski, Angelika, Patel, Kaelan R., Castro, Colleen D., Muthyala, Ramaiah, Sham, Yuk Y., Taylor, Erika A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9068772/
https://www.ncbi.nlm.nih.gov/pubmed/35508636
http://dx.doi.org/10.1038/s41598-022-10776-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9068772/
https://www.ncbi.nlm.nih.gov/pubmed/35508636
http://dx.doi.org/10.1038/s41598-022-10776-x

Ejemplares similares